SI-BONE Management

Management criteria checks 3/4

SI-BONE's CEO is Laura Francis, appointed in Apr 2021, has a tenure of 3.58 years. total yearly compensation is $3.71M, comprised of 16.8% salary and 83.2% bonuses, including company stock and options. directly owns 0.84% of the company’s shares, worth €4.44M. The average tenure of the management team and the board of directors is 3.6 years and 13.9 years respectively.

Key information

Laura Francis

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage	16.8%
CEO tenure	3.6yrs
CEO ownership	0.8%
Management average tenure	3.6yrs
Board average tenure	13.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Laura Francis's remuneration changed compared to SI-BONE's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$37m
Jun 30 2024	n/a	n/a	-US$41m
Mar 31 2024	n/a	n/a	-US$43m
Dec 31 2023	US$4m	US$622k	-US$43m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$55m
Dec 31 2022	US$5m	US$604k	-US$61m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$62m
Dec 31 2021	US$3m	US$527k	-US$57m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$2m	US$386k	-US$44m
Sep 30 2020	n/a	n/a	-US$44m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$2m	US$375k	-US$38m
Sep 30 2019	n/a	n/a	-US$35m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$734k	US$319k	-US$17m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$21m
Dec 31 2017	US$518k	US$302k	-US$23m

Compensation vs Market: Laura's total compensation ($USD3.71M) is above average for companies of similar size in the German market ($USD1.03M).

Compensation vs Earnings: Laura's compensation has been consistent with company performance over the past year.

CEO

Laura Francis (57 yo)

3.6yrs

Tenure

US$3,713,871

Compensation

Ms. Laura A. Francis, MBA, serves as Chief Executive Officer and Director at SI-BONE, Inc. since April 18, 2021. She was Chief Financial Officer of SI-Bone Inc. since May 26, 2015 until April 18, 2021 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Laura Francis	CEO & Director	3.6yrs	US$3.71m	0.84% € 4.4m
Anshul Maheshwari	Chief Financial Officer	3.6yrs	US$1.86m	0.17% € 881.8k
Anthony Recupero	President of Commercial Operations	8.3yrs	US$2.06m	0.23% € 1.2m
Jeff Bertolini	Senior Vice President of Operations & Information Technology	2.3yrs	no data	no data
Scott Yerby	Senior VP of Engineering & CTO	no data	no data	no data
Saqib Iqbal	Director of FP&A and Investor Relations	no data	no data	no data
Michael Pisetsky	Chief Business & Legal Affairs Officer	8.3yrs	no data	no data
Aimee Einstein	Vice President of People & Culture	2.8yrs	no data	no data
Daniel Cher	Senior Vice President of Clinical & Regulatory Affairs	3.4yrs	no data	no data
W. Reckling	Chief Medical Officer & VP of Medical Affairs	no data	no data	no data
Nikolas Kerr	Senior Vice President of Product	3.6yrs	no data	no data
Troy Wahlenmaier	Senior Vice President of US Sales	less than a year	no data	no data

3.6yrs

Average Tenure

56.5yo

Average Age

Experienced Management: 2K3's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Laura Francis	CEO & Director	3.6yrs	US$3.71m	0.84% € 4.4m
Timothy Davis	Lead Independent Director	16.6yrs	US$211.30k	0.092% € 484.9k
Gregory Hinckley	Independent Director	13.8yrs	US$191.30k	0.38% € 2.0m
Jeryl Hilleman	Independent Director	4.9yrs	US$206.30k	0.025% € 131.7k
John Freund	Independent Director	11.8yrs	US$188.30k	0.31% € 1.6m
Ralph Rashbaum	Member of Medical Advisory Board	14.8yrs	no data	no data
Steven Garfin	Member of Medical Advisory Board	14.8yrs	no data	no data
Frank Phillips	Member of Medical Advisory Board	14.8yrs	no data	no data
Jeffrey Dunn	Executive Chairman	16.6yrs	US$551.18k	0.26% € 1.4m
A. Shamie	Member of Medical Advisory Board	13.9yrs	no data	no data
Mika Nishimura	Independent Director	3.7yrs	US$188.30k	0.046% € 243.0k
Jonathan Hyde	Member of Surgeon Advisory Board	no data	no data	no data

13.9yrs

Average Tenure

67yo

Average Age

Experienced Board: 2K3's board of directors are seasoned and experienced ( 13.9 years average tenure).

SI-BONE Management

Management criteria checks 3/4

Key information

Recent management updates

CEO & Director recently sold €126k worth of stock

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

CEO & Director recently sold €751k worth of stock

Executive Chairman recently sold €130k worth of stock

CEO & Director recently sold €173k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2023)

SI-BONE, Inc. Updates Financial Guidance for the Year 2024

SI-BONE, Inc. Updates Financial Guidance for the Year 2024

SI-BONE, Inc. to Report Q3, 2024 Results on Nov 12, 2024

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

CEO & Director recently sold €126k worth of stock

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.30 loss in 2Q 2023)

SI-BONE, Inc. Revises Financial Guidance for 2024

New minor risk - Share price stability

SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Share price stability

Si-Bone, Inc. Increases Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.32 loss in 1Q 2023)

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024

New minor risk - Profitability

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$1.13 loss per share (vs US$1.79 loss in FY 2022)

Forecast to breakeven in 2026

CEO & Director recently sold €751k worth of stock

SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Forecast to breakeven in 2026

SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Executive Chairman recently sold €130k worth of stock

SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.41 loss in 3Q 2022)

New major risk - Revenue and earnings growth

SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods

CEO & Director recently sold €173k worth of stock

Independent Director recently sold €561k worth of stock

SI-BONE, Inc. Revises Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.30 loss per share (vs US$0.54 loss in 2Q 2022)

SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO & Director recently sold €206k worth of stock

SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.

First quarter 2023 earnings released: US$0.32 loss per share (vs US$0.52 loss in 1Q 2022)

SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023

SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System

Executive Chairman recently sold €101k worth of stock

Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.48 loss in 3Q 2021)

SI-BONE, Inc. Updates Revenue Guidance for the Year 2022

SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Executive Chairman recently sold €135k worth of stock

SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.42 loss in 2Q 2021)

SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite

Executive Chairman recently sold €68k worth of stock

First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.37 loss in 1Q 2021)

SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022

SI-BONE, Inc., Annual General Meeting, Jun 16, 2022

SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment

SI-BONE, Inc. to Report Q1, 2022 Results on May 09, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022

Executive Chairman recently sold €80k worth of stock

SI-BONE, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Executive Chairman recently sold €122k worth of stock

Third quarter 2021 earnings released: US$0.48 loss per share (vs US$0.33 loss in 3Q 2020)

Executive Chairman recently sold €120k worth of stock

Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.44 loss in 2Q 2020)

SI-BONE, Inc. Provides Earnings Guidance for the Year 2021

Executive Chairman recently sold €52k worth of stock

Si-Bone, Inc. Announces the Introduction of the Si-Bone Simulator Powered by Medability for Ifuse Surgeon Training and Education